SYLENTIS

Sylentis, a PharmaMar Group company, announces the FYDES study to evaluate the safety of tivanisiran in patients with dry eye disease has met its primary endpoint... Our ambition is to become the most highly valued company in the industry by patients and healthcare professionals. At Sylentis, we aim to increase our competitiveness as a pharmaceutical company by advancing the therapeutic areas in which we research and develop drugs.

Also known as: Sylentis, S.A., SYLENTIS, S.A.U.

Primary location: Madrid Spain